Rama Melkote, MSc, MPH

Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results From the Clinical Development Program

Aim: To evaluate the cardiac safety of esketamine nasal spray administered to patients with treatment-resistant depression (TRD). Methods: Cardiovascular (CV) effects of esketamine nasal...

Jaskaran Singh , MD;

Teodora Doherty , MD;

Michael Weber , MD, PhD;

Ewa Wajs , MD, PhD;

Rama Melkote , MSc, MPH;

Janice Miller , MD;

11/22/2019

Randomized, Double-Blind Study of Fixed-Dose Esketamine Nasal Spray Plus Oral Antidepressant vs. Active Control in Treatment-Resistant Depression

Aim: Compare efficacy and safety of fixed doses of esketamine nasal spray plus oral antidepressant (AD) to oral AD plus placebo nasal spray for treatment-resistant depression (TRD). Met...

Dawn Vitagliano , BA;

Michael Liebowitz , MD;

Arun Ravindran , MB, PhD, MSc;

Raphael Gaillard , MD, PhD;

Hans van den Ameele , MD;

Maurizio Fava , MD, PhD;

Ella Daly , MB, BCh, BAO;

Madhukar Trivedi , MD;

Wayne Drevets , MD;

Jaskaran Singh , MD;

Rosanne Lane , MD, MSc, MS;

Maggie Fedgchin , PharmD;